<DOC>
	<DOCNO>NCT01417780</DOCNO>
	<brief_summary>A study evaluate safety pharmacokinetics profile different dos AB103 administer patient diagnose Necrotizing Soft Tissue Infections schedule urgent surgical intervention part standard care .</brief_summary>
	<brief_title>Evaluation Safety , PK Immunomodulatory Effects AB103 Necrotizing Soft Tissue Infections Patients</brief_title>
	<detailed_description>A study evaluate safety pharmacokinetics profile different dos AB103 administer patient diagnose Necrotizing Soft Tissue Infections schedule urgent surgical intervention part standard care . The primary study hypothesis AB-103 administer safely patient present Necrotizing Soft Tissue Infections . Secondary endpoint efficacy exploratory descriptive analysis specific efficacy endpoint three outcome domain demonstrate treatment benefit AB103 comparison placebo patient Necrotizing Soft Tissue Infections . The efficacy domains : 1 . Clinical status domain 2 . Pharmacoeconomics domain 3 . Systemic local inflammatory biomarker domain</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<criteria>Inclusion Criteria Clinical diagnosis NSTI due bacterial infection ( Necrotizing Fasciitis , Group A streptococcal infection non group A streptococcal infection , Fournier 's gangrene , Bacterial synergistic gangrene , Synergistic Necrotizing Cellulitis , Clostridial gas gangrene/ myonecrosis ) may support specific sign symptom , e.g . tense edema outside area compromise skin , pain disproportionate appearance , skin discoloration , ecchymosis , blisters/bullae , necrosis , tense edema , crepitus and/or subcutaneous gas AND decision urgent surgical exploration debridement ; Patient receive study drug prior surgery need definite diagnosis NSTI confirm surgically ( e.g . presence necrotic tissue , thrombose vessel subcutaneous tissue , lack bleed `` dishwater '' ( cloudy , thin , gray ) fluid ) order get drug operation ; IV drug administration within 6 hour clinical diagnosis document decision urgent surgical exploration debridement ; Signed date ICF define IRB , applicable , California Bill Rights . By sign ICF , patient agree release medical record pursuant current Health Insurance Portability Accountability Act ( HIPAA ) Guidelines . If patient unable comprehend sign ICF , patient 's legally acceptable representative may sign ICF ; Exclusion Criteria Age &lt; 18 year ; Weight &gt; 150 Kg / 330 pound ; Pregnant lactate woman ; Female childbearing potential , patient must negative beta subunit hCG pregnancy test immediately prior study entry ( perform urine blood test , whichever faster ) ; Patient operate least current NSTI infection curative deep tissue debridement ( diagnostic surgery allow enter study ) ; Known HIV infection CD4 count &lt; 200 cells/mm3 &lt; 14 % lymphocyte ; Diabetic patient ankle infection ; Patients overt peripheral vascular disease involve area condition associate ischemic ulcer /or symptom inadequate vascular supply ( e.g . intermittent claudication ) limb amputation consider likely within 7 day ; Current status : . Mean arterial pressure &lt; 50 mmHg and/or systolic blood pressure &lt; 70 mmHg despite treatment vasopressor and/or IV fluid b. patient respiratory failure SaO2 80 % achieve c. patient refractory coagulopathy ( INR &gt; 3 ) d. thrombocytopenia ( platelet count &lt; 20,000 ) partially correct administration appropriate factor , e. likely severe neurological impairment secondary cardiac arrest . Patients cardiac arrest require cardiopulmonary resuscitation within past 30 day ; Patient expect survive 30 day underlie medical condition , poorly control neoplasm ( e.g . Stage III IV cancer ) ; Any concurrent medical condition , opinion investigator , may compromise safety objective study patient benefit treatment , ( e.g . end stage organ disease { CHF { NYHA class IIIIV } , COPD { stage IIIIV } , Liver dysfunction { ChildsPugh class C } , Renal dysfunction { Dialysis } ) , immunosuppression , receive receive chemotherapy know severe neutropenia &lt; 1,000 cells/mm3 ; Patients Necrotizing Soft Tissue Infection post intraabdominal operation ; Patient burn wound ; Patient patient 's family commit aggressive management patient 's condition , combination necrotizing skin infection underlie illness make unlikely life support maintain ; Previous enrolment previous clinical trial involve investigational drug medical device within 30 day provision write informed consent study within five half live investigational drug , whichever longer ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>